NZ711344B2 - Macrocyclic deaza-purinones for the treatment of viral infections - Google Patents

Abstract

This invention relates to macrocyclic deaza-purinones derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Description

-1 _ Macrocyclic deaza-purinones for the treatment of viral infections This invention relates to macrocyclic deaza-purinones derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

The present invention relates to the use of macrocyclic deaza-purinones tives in the treatment of viral infections, immune or inflammatory disorders, whereby the modulation, 0r agonism, of toll-like-receptors (TLRs) is involved. Toll-Like ors are primary transmembrane proteins characterized by an extracellular leucine rich domain and a cytoplasmic extension that contains a conserved region. The innate immune system can recognize pathogen- associated lar patterns via these TLRs expressed on the cell surface of certain types of immune cells. Recognition of foreign ens activates the production of cytokines and upregulation of co-stimulatory molecules on phagocytes. This leads to the modulation of T cell behaviour.

It has been estimated that most mammalian species have n ten and fifteen types of Toll- like ors. Thirteen TLRs (named TLRl to TLRl3) have been identified in humans and mice together, and equivalent forms of many of these have been found in other mammalian species. r, equivalents of certain TLR found in humans are not present in all mammals. For example, a gene coding for a n analogous to TLRlO in humans is present in mice, but appears to have been damaged at some point in the past by a retrovirus. On the other hand, mice express TLRs ll, 12, and 13, none of which are represented in humans. Other mammals may express TLRs which are not found in humans. Other mmalian s may have TLRs distinct from mammals, as demonstrated by TLRl4, which is found in the Takifilgu pufferfish.

This may complicate the process of using experimental animals as models of human innate immunity.

For ed s on toll-like receptors see the following journal articles. Hoffmann, J.A., Nature, 426, p33-38, 2003; Akira, S., Takeda, K., and Kaisho, T., Annual Rev. Immunology, 21, p335-376, 2003; Ulevitch, R. J., Nature Reviews: Immunology, 4, p512-520, 2004.

Compounds indicating activity on ike receptors have been previously described such as purine derivatives in 17670, adenine tives in WO 98/01448 and WO 99/28321, and pyrimidines in .

However, there exists a strong need for novel Toll-Like receptor modulators having preferred selectivity, higher potency, higher metabolic stability, and an improved safety profile compared to the compounds ofthe prior art.

In the treatment of certain viral infections, regular injections of interferon (IFN—alfa) can be administered, as is the case for hepatitis C virus (HCV). For more ation see Fried et al.

Peginterferon—alfa plus ribavirin for chronic hepatitis C virus infection, N Engl JMed 2002; 347: . Orally available small molecule IFN inducers offer the potential advantages of reduced immunogenicity and convenience of administration. Thus, novel IFN inducers are potentially ive new class of drugs for treating virus infections. An example of a small molecule IFN inducer having antiviral effect see De Clercq, E.; Descamps, J.; De Somer, P. Science 1978, 200, 563-565.

IFN-alfa is also given in combination with other drugs in the treatment of n types of cancer (Eur. J. Cancer 46, 7, and Cancer Res. 1992, 52, 1056). TLR 7/8 agonists are also of interest as vaccine adjuvants e of their ability to induce pronounced Th1 se (Hum.

Vaccines 2010, 6, 322-335, and Hum. Vaccines 2009, 5, 381−394).

In accordance with the present invention a compound of formula (I) is provided and pharmaceutically ed salts thereof, wherein X is O, NH or S Y represents an aromatic ring or heterocyclic ring comprising at least a nitrogen, ally substituted by one or more substituents independently selected from C1-6alkyl, C1-4alkoxy, trifluoromethyl or halogen, Z represents C1-10 saturated or unsaturated alkyl optionally substituted by an alkyl or alkylhydroxyl; or Z represents C1-6alkyl -NH-C(O)- C1-6alkyl-, C1-6alkyl-NH- or C1-6alkyl -NH-C(O)- C1-6alkyl -O-; or Z represents C1-10alkyl -O- wherein said alkyl is unsaturated or saturated and can optionally be substituted by an alkyl or alkylhydroxyl , or Z represents kyl-O-C1-6alkyl- wherein said alkyl is unsaturated or ted and can optionally be substituted by an alkyl or alkylhydroxyl or Z represents C1-6alkyl-O-C1-6alkyl-O- wherein said alkyl is unsaturated or saturated and can optionally be substituted by an alkyl or alkylhydroxyl.

Preferred compounds having one of the following formula’s according to the invention were selected from the group of: Part of the invention is also a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof together with one or more pharmaceutically able excipients, diluents or rs.

Furthermore to the invention belongs a compound of a (I) or a pharmaceutically able salt, solvate or polymorph thereof or a ceutical composition above mentioned for use as a medicament.

The invention also relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof or a pharmaceutical ition above mentioned for use in the treatment of a disorder in which the modulation of TLR7 is involved.

The term "alkyl" refers to a straight-chain or branched-chain mostly saturated (but in ic compounds according to the invention being unsaturated) aliphatic hydrocarbon containing the specified number of carbon atoms.

The term "halogen" refers to fluorine, chlorine, bromine or .

The term "alkoxy" refers to an alkyl (carbon and hydrogen chain) group singular bonded to oxygen like for instance a methoxy group or ethoxy group.

Pharmaceutically acceptable salts of the nds of formula (I) include the acid addition and base salts thereof Suitable acid addition salts are formed from acids which form non-toxic salts.

Suitable base salts are formed from bases which form non-toxic salts.

The compounds of the invention may also exist in unsolvated and solvated forms. The term "solvate" is used herein to describe a molecular complex comprising the nd of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.

The term "polymorph" refers to the ability of the compound of the invention to exist in more than one form or crystal ure.

The nds of the invention can be present in a so-called "tautomer(s)" formation refering to isomers of c compounds that readily interconvert by a chemical reaction called tautomerization. This reaction results in the formal migration of a hydrogen atom or proton, accompanied by a switch of a single bond and adjacent double bond.

The compounds of the present invention may be administered as crystalline or amorphous products. They may be obtained for example as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs. lly, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term "excipient" is used herein to describe any ingredient other than the compound(s) of the invention. The choice of excipient depends largely on s such as the particular mode of administration, the effect ofthe excipient on solubility and stability, and the nature of the dosage form.

The compounds of the present ion or any subgroup thereofmay be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the ular nd, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable r, which carrier may take a wide variety of forms depending on the form of preparation desired for stration. These pharmaceutical compositions are desirably in unitary dosage form suitable, for example, for oral, rectal, or percutaneous administration. For e, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions, and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage 3O unit forms, in which case solid pharmaceutical rs are obviously employed. Also included are solid form preparations that can be converted, shortly before use, to liquid forms. In the compositions suitable for aneous administration, the carrier optionally comprises a penetration enhancing agent and/or a le wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a icant rious effect on the skin. Said additives may facilitate the administration to the skin and/or may be l for ing the desired compositions. These compositions may be administered in various ways, e. g., as a transdermal patch, as a spot-on, as an ointment. The compounds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations ed in the art for administration via this way. Thus, in general the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined ty of active ient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or sions and the like, and segregated multiples f Those of skill in the treatment of infectious diseases will be able to determine the effective amount from the test results presented hereinafter. In l it is contemplated that an effective daily amount would be from 0.01 mg/kg to 50 mg/kg body weight, more preferably from 0.1 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the ed dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.

The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the ular condition being treated, the severity of the condition being treated, the age, weight and general al condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art.

Furthermore, it is evident that the effective amount may be lowered or sed ing on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective amount ranges mentioned above are therefore only guidelines and are not intended to limit the scope or use of the invention to any extent.

Overall Scheme in the preparation of final products: method 1 A[/ O\/\ I \ O\/\ J): O K2003 acetone NHs aq 3'21.on)LO N / NH2 NH2 HON R OZN / Grubbs-Hoveyda gzN / N 2nd generation I Fe, ACOH N 0*N \ HO , I o —> / \ NaH, THF Oi\O/\O N o DCE ) water / 0 KO/O o SOCI2 o CHZCIZ HO CI (31 B1 Synthesis of ediate B1 SOC12 (80 mL; 1.11 mol) was added drop wise to a mixture of G1 (19.1 g; 111 mmol) in CH2C12 (230 mL) at rt. The mixture was stirred at rt for 16 h. The solvent was ated and the residue was solubilized in CH2C12 and treated with a saturated aqueous solution of NaHC03 until basic pH. The layers were separated and the s layer was extracted with CH2C12 (twice). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo to give 20.1 g of a brown oil. The crude compound was used in the next step without further purification.

O\/\ 2BO/JEHIZO WE/OH/ cho3N:|cetone 5E1?) Synthesis of intermediate C1 The reaction was performed on two batches in parallel (13.6 mmol and 27.1 mmol ofA1).

To a solution of A1 (5.0 g; 13.6 mmol) and K2C03 (3.75 g; 27.1 mmol) in acetone (100 mL) were added B1 (4.46 g; 24.4 mmol) and NaI (2.23 g; 14.9 mmol) at rt. The mixture was stirred at rt for 16 h. The mixture was filtered and the filtrate was evaporated in vacuo to give a brown oil.

The two batches were combined and purified by preparative LC (Irregular SiOH 15-40 um, 220 g Grace, mobile phase gradient: CHzClz/EtOAc from 100/0 to 80/20). The fractions ning product were combined and the solvent was d in vacuo to give 18.6 g of intermediate C1 (89% yield).

JOAN O m, CAN ' 2 Br N Br KI\ Br N NH2 D1 sis of intermediate D1 To a solution of C1 (18.6 g; 36.1 mmol) in THF (300 mL) was added an aqueous on of NH3 (30%) (290 mL) at rt, and the mixture was d at rt for 16 h. The mixture was taken up with EtOAc and saturated NaCl solution, the layers were separated and the organic layer was dried over MgSO4, filtered and the solvent was removed under reduced pressure to give 16.7 g of a yellow-orange oil. The crude was dried under high vacuum to give 16.5 g of a sticky - orange solid, which was used directly in the next step. 0\/\ i HOV OZN o N —’ o \ N o/V/ 2 No2 NaH THF / A /\ | O O Br N NH2 Synthesis of intermediate E1 NaH (60% in oil) (1.75 g; 43.7 mmol) was added portion wise to allyl alcohol (50 mL) at rt. The mixture was stirred at rt for 30 min before being added drop wise to a solution of D1 (5 g; 11.1 mmol) in THF (124 mL) at 0°C. The resulting mixture was then stirred at rt for 1 h and was poured in saturated NH4C1 aqueous solution. EtOAc and saturated NaCl s solution were added, the layers were separated and the s layer was extracted with EtOAc (once). The combined organic layers were dried over MgSO4, filtered and the t was d under d pressure to give a yellow oil. The crude compound was purified by preparative LC (Irregular SiOH 15-40 um, 120 g Grace, liquid injection, mobile phase gradient: from Heptane/EtOAc 100/0 to 50/50) to give 4.04 g of intermediate E1 as a yellow oil (79% . k OzNfl Grubbs-HoveydaD | 2nd generation \ ON/ 0 A DCE o O/\ Synthesis of ediate Fl The reaction was performed in 2 batches of 850 mg and 2 batches of 1 g of El.

Herein is the ure for one batch of 850 mg: In a schlenk flask, a solution of El (0.85 g; 1.98 mmol) and chlorodicyclohexylborane (1M solution in hexane) (400 uL; 400 umol) in dichloroethane (570 mL) was stirred at 80°C under N2 atmosphere for 1 h. Grubbs-Hoveyda catalyst 211d generation (124 mg; 198 umol) was added and the e was stirred at 120°C for 16 h. The mixture was degassed by N2 bubbling for 10 min and further Grubbs-Hoveyda catalyst 2Ild generation (124 mg; 198 umol) and chlorodicyclohexylborane (1M solution in hexane) (400 uL; 400 umol) were added. The mixture was stirred at 120°C for 20 h.

The 2 batches were mixed and a ruthenium scavenger (SiliaBond DMT from SiliCycle) (10.4 g; 6.35 mmol) was added and the mixture was stirred at rt for 20 h. The reaction mixture was filtered through a pad of celite and the solvent was removed under reduced pressure to give a brown residue.

The residue was combined with the residue obtained from the two batches of 1 g of E1. The resulting brown e was purified by preparative LC (Irregular SiOH 15-40 um, 120 g Grace, dry loading, mobile phase gradient: from Heptane/EtOAc 100/0 to 0/100) to give 1.19 g of a brown solid. The brown solid was further purified by preparative LC (Stationary phase: irregular bare silica 40 g, mobile phase gradient: from CHzClz/EtOAc 90/10 to 80/20) to give 705 mg of a yellow solid. The yellow solid was further purified by achiral SFC (stationary phase: Amino 6um 150x21.2mm), mobile phase: Gradient from 85% C02, 15% MeOH to 65% C02, 35% MeOH) to give 660 mg of intermediate F1 as a yellow solid (19% yield, E ).

OzN/ N o N / A \l Fe,AcOH N O "0%m 3 N ?/ ~\ 0? Synthesis of final compound 1 A mixture of F1 (570 mg; 1.42 mmol) and iron (795 mg; 14.2 mmol) in AcOH (21 mL) and water (4.2 mL) was d at 50°C for 2 h. The mixture was concentrated until dryness. DMF was added, the mixture was sonicated, heated and filtered through a pad of celite and the celite was rinsed with hot DMF. An iron scavenger (SiliaBond Imidazole from SiliCycle) (25.4 g; 29.5 mmol) was added to the filtrate and the mixture was stirred at rt for 16 h. The mixture was filtered through celite, the celite was rinsed with DMF and the filtrate was concentrated in vacuo to give 620 mg of a brown solid. The crude was purified by preparative LC (irregular SiOH, 15- 40 um, 30 g Merck, mobile phase gradient: from CHzClz/MeOH/NHgaq 98/2/02 to 85/15/ 1.5) to give 360 mg of final compound 1 as an ite solid (75% yield). 2): O PPh3—>/DIAD DAN HF 2 / Br N Br Alternative synthesis of intermediate C1 At 0°C, diisopropylazodicarboxylate (DIAD) (3.0 mL,15.0 mmol) was added drop wise to a mixture ofAl (3.70 g, 10.028 mmol), G1 (1.98 g, 12.0 mmol) and PPh3 (3.94 g, 15.0 mmol) in THF (70 mL). The e was stirred at rt for 12 h. EtOAc and water were added. The layers were decanted. The organic layer was washed with water, dried over MgSO4, filtered and the t was ated. The crude was purified by preparative LC on (Irregular SiOH 20-45 um 450 g Matrex), mobile phase (85% Heptane, 15% AcOEt) to give 4.5 g of intermediate C1 (87% yield). 2014/056270 -1 0- Overall Scheme in the preparation of final products: method 2 NH2 NH2 02N / Wlkinson'scatalyst 02N / oi N N THF/MeOH O FeyAcoH \ Ho— Synthesis of final compound 2 Compound 2 was obtained using the procedure to prepare compound 1 (54 mg, 44% .

Overall Scheme in the preparation of final products: method 3 AL / 0 O NH K2C03Y acetone OJLN NH3 aq )fINO —’ IN/ N | + Nal 02 Br \N / Br CI \ | Br N Br \ A1 '1 Br N NH2 NH2 NH2 0 N2 HOW \ IN Grubbs st 002N/ N OiN N / 2nd Generation I Fe, ACOH N , N O/\/\ | 0 HO— | N02 + Nal 2 / Br N Br CI I Br N Br A1 I1 Synthesis of intermediate J 1 11 (5.9 g; 35.6 mmol) was added to a solution of A1 (7.3 g; 19.8 mmol), K2C03 (5.5 g; 39.6 mmol) and NaI (3.3 g; 21.8 mmol) in acetone (145 mL). The mixture was stirred at rt for 20 h.

The mixture was filtered through a pad of celite and the filtrate was evaporated in vacuo to give an orange solid. The residue was taken up in CHzClz. The precipitate was filtered and the e was concentrated in vacuo to give 13 g of a yellow oil. The crude compound was purified by preparative LC (Irregular SiOH 15-40 um, 300 g Interchim, mobile phase gradient: from e/EtOAc 100/0 to 80/20). The fractions containing product were ed and the solvent was removed in vacuo to give 7.1 g of ediate J 1 (72% yield) as a yellow oil.

JL 0 NH3aq )3 N —’ B/ENIB o N / THF 2fl\ No2 r r Br N NH2 Synthesis of intermediate K1 In a schlenk flask, a solution of J 1 (7.1 g; 14.2 mmol) in THF (130 mL) and an aqueous solution ofNH3 (30%) (130 mL) was stirred at rt for 16 h. The mixture was taken up with EtOAc and a ted water solution of NaCl, layers were separated. The organic layer was dried over MgSO4, filtered and concentrated in vacuo to give 6.4 g of a yellow oil (100% yield). 2014/056270 0 02N / N o N \ om 2 N / NaH,THF | A /\ o 0 Br N NH2 K1 L1 Synthesis of intermediate Ll NaH (2.2 g; 54.2 mmol) was added portion wise at rt and under N2 here to n—l-ol (76 mL). The mixture was stirred at rt for 30 min before being added drop wise at 0°C to a solution of K1 (5.9 g; 13.6 mmol) in THF (150 mL). The resulting mixture was stirred at 0°C for 1 h. The mixture was poured into an aqueous saturated NH4Cl solution. EtOAc and satured aqueous NaCl solution were added, the layers were separated. The organic layers was dried over MgSO4, filtered and concentrated in vacuo to give a yellow residue which was azeotropically distilled with toluene (once) to give 6.6 g of a yellow oil. The crude compound was purified by preparative LC (Irregular SiOH 15-40 um, 220 g Grace, mobile phase gradient: from Heptane/EtOAc 100/0 to 50/50). The fractions containing product were combined and the solvent was removed in vacuo to give 4.46 g of intermediate L1 (77% yield) as a yellow oil.

NH2 NH2 0 N O N 2 fl O2 / \ Grubbs catalyst |N \ 2nd enerat'on \ 9 ' N O/\/\ CAN 0 CH CI / Synthesis of intermediate M1 The reaction was performed in 2 batches. l procedure for one batch: A solution ole (2.45 g; 5.75 mmol) in dry CHzClz (1.7 L) was ed by N2 bubbling for 15 min. Grubbs catalyst 211d generation (488 mg; 574 umol) was added and the mixture was stirred at rt for 72 h. SiliaBond DMT (7.66 g; 4.59 mmol) was added and the mixture was stirred at rt for 16 h. The 2 batches were combined and filtered h celite. The filtrate was concentrated in vacuo to give a black solid. The crude compound was d by ative LC (Irregular SiOH 15-40 um, 150 g Merck, mobile phase gradient: from Heptane/EtOAc 100/0 to 50/50).

The fractions containing product were combined and the solvent was removed in vacuo to give -1 3- 230 mg of fraction 1 and 2.3 g of fraction 2. Fraction 2 was ified by preparative LC onary phase: irregular SiOH 40 um 120 g, mobile phase: Heptane/CHzClz/MeOH 55/43/2).

The isolated compound was combined with fiaction 1 and purified by achiral SFC (Stationary phase: Chiralpak IC 5 um 250x20 mm, mobile phase: 70% C02, 30% iPrOH) to give 1.51 g of intermediate Ml (33% yield, isomer E) as a yellow solid.

OZN / N 0 N / \l Fe AcOH N A ’ I N o , Ho— Overall Scheme in the preparation of final products: method 4 NH2 NH2 NH2 OZN / N Wilkinson'scatalyst OZN / / O I o N AGOH AN \ THF/MeOH ‘N szPd/C :2" / Ho— OAN \ ’ I \ o \ 0 N o / H2 EtOH O | | M1 N1 01 -1 4- Synthesis of intermediate Nl son’s catalyst (46 mg; 50.2 umol) was added to a solution of M1 (200 mg; 502 umol) in THF/MeOH (50/50) (50 mL) purged by N2 bubbling for 15 min. The mixture was hydrogenated (7 bars) at rt for 20 h. The mixture was purged by N2 ng for 15 min, further Wilkinson’s catalyst (46 mg; 50.2 umol) was added and the on mixture was hydrogenated (7 bars) at rt for 16 h. The on mixture was trated in vacuo to give a green oil. The oil was purified by preparative LC (Irregular SiOH 15-40 um, 25 g Merck, dry loading, mobile phase gradient: from Heptane/EtOAc 100/0 to 70/30) to give 130 mg of intermediate N1 as a yellow solid (66% yield).

Synthesis of intermediate 01 In a pressure vessel reactor, N1 (110 mg; 275 umol) was hydrogenated in EtOH (5 mL) with Pd/C (10%) (30 mg; 28.5 umol) as catalyst at 40°C (3 bars) for 6 h. The catalyst was d by filtration over celite, the celite was washed with EtOH and the filtrate was evaporated under vacuum to give 100 mg of a yellow residue (98% yield). Intermediate 01 was used in the next step without filrther purification.

Synthesis of final compound 4 In a sealed tube, 01 (100 mg; 270 umol) in pure acetic acid (5 mL) was stirred at rt for 90 min.

The solvent was removed under reduced pressure to give a yellow residue. The residue was taken up with CHzClz and the solvent was removed under reduced pressure (twice) to give 87 mg of a -green solid. The solid was azeotropically distilled with toluene (four times), and was then triturated and sonicated in EtzO. The mixture was filtered off (glass frit n05) to give 75 mg of final compound 4 (77% yield, acetate salt). -1 5- Overall Scheme in the preparation of final ts: method 5 I / ON\ 0V | N \ 0V 2 K2C03 acetone NH3 aq f1 OJLN O/\/ Nal EHZOZ 2 / N02 \L NH2 NH2 NH2 ON Grubbs—Hove da OZN / N / N N HOW 2 / N O .y o Ho— I / N\ 0V I o N\ 0 O/\/ OJLN NH—3>aq 2 N02 THF )fii Br \N Br -1 5- sis of intermediate R1 In a schlenk flask, to a solution of Q1 (3.28 g; 6.36 mmol) in THF (52 mL), was added an aqueous on ofNH3 (30%) (52 mL) at rt. The mixture was stirred at rt for 26 h and further aqueous solution of NH3 (10 mL) was added and the mixture was d at rt for 4 h. The mixture was taken up with EtOAc and saturated aqueous solution of NaCl, the layers were ted and the organic layer was dried over MgSO4, filtered and the solvent was removed under reduced pressure to give 2.74 g of ediate R1 as a yellow oil (87% yield).

N‘ 0V o \h NH2 OJLN Ho/\/\ 02N / 0 IN 2 N02 —> \ OW / / N | NaH’THF I Br \N \ N GAGA Synthesis of intermediate Sl NaH (60% in oil) (888 mg; 22.2 mmol) was added portion wise to 3-buten—l-ol (30 mL; 354 mol) at rt. The mixture was stirred at rt for 30 min before being added drop wise to a on ofR1 (2.74 g; 5.63 mmol) in THF (62 mL) at 0°C. The resulting mixture was stirred at rt for l h and was poured in NH4Cl saturated aqueous solution. EtOAc and NaCl saturated aqueous solution were added, the layers were ted and the aqueous layer was extracted with EtOAc (once). The combined organic layers were dried over MgSO4, filtered and the solvent was removed under reduced pressure to give a yellow oil. The oil was purified by preparative LC (Irregular SiOH 15-40 um, 80 g Grace, dry loading, mobile phase gradient: from Heptane/EtOAc 100/0 to 20/80) to give 1.06 g of intermediate S1 as a yellow residue (42% yield).

\ NH2 0 2Nfl g"Ebb:::tleydaL 82 n genera |0n / N OW L0AM /N|\Nfiko Synthesis of intermediate T1 The reaction was performed in two batches of 480 mg of intermediate S l.

Herein is reported the procedure for one batch: -1 7- In a ck flask, a on of S1 (480 mg; 1.08 mmol) and chlorodicyclohexylborane (1M in hexane) (216 uL; 216 umol) in dry dichloroethane (300 mL) was stirred at 80°C and under N2 atmosphere for 1 h. Grubbs-Hoveyda catalyst 2Ild generation (68 mg; 108 umol) was added and the mixture was stirred at 120°C for 2 h.

The two s were mixed, SiliaBond DMT (2.84 g; 1.73 mmol) was added and the mixture was stirred at rt for 20 h.

The mixture was filtered through a pad of celite, the celite was washed with EtOAc and the filtrate was evaporated in vacuo to give a brown solid. The brown solid was purified by preparative LC (Irregular SiOH 15-40 um, 40 g Grace, dry loading, mobile phase gradient: CHzClz/EtOAc from 100/0 to 20/80) to give 610 mg of a yellow residue (mixture of E and Z isomers, intermediate U1). 310 mg of intermediate U1 was d by Reverse phase (Stationary phase: Nucleodur-Sphinx rp 5um 21x150 mm, mobile phase: Gradient from 70% formic acid 0.1%, 30% MeCN to 0% formic acid 0.1%, 100% MeCN) to give 195 mg ofintermediate T1 (E isomer) as a yellow solid (22% yield).

NH2 NH2 OZN / N / N N / O m Fe,AcOH HO— The residue was diluted in DMF and filtered h a pad of celite. SiliaBond imidazole (12.7 g; 14.7 mmol) was added to the filtrate and the mixture was stirred at rt for 16 h. The mixture was filtered through a pad of celite and the filtrate was evaporated in vacuo to give a brown solid. The brown solid was purified by preparative LC (irregular SiOH 15-40 um, 12 g Grace, dry loading, mobile phase gradient: from CHzClz/MeOH/NHgaq 97/3/03 to 80/20/2) to give 65 mg of an off-white solid. The solid was purified by Reverse phase onary phase: X-Bridge- C18 5um 30*150mm, mobile phase gradient: from H20(0.5%NH4C03)/MeOH 70/30 to 0/100) to give 43 mg of final nd 5 as a white solid (31% yield, E isomer). -1 8- Overall Scheme in the preparation of final products: method 6 NH2 NHz OZN / O Ho— Synthesis of final compound 6 A mixture ofVl (238 mg; 359 umol) and iron (120 mg; 2.16 mmol) in acetic acid (20 mL) and water (2.2 mL) was stirred at 80°C for 6 h. Further iron (120 mg; 2.16 mmol) was added and the mixture was stirred at 80°C for 20 h. Further iron (120 mg; 2.16 mmol) was added and the mixture was stirred at 80°C for 5 h. The mixture was concentrated in vacuo to give a residue.

The residue was diluted in DMF and d through a pad of celite. SiliaBond imidazole (11.1 g; 12.9 mmol) was added to the filtrate and the mixture was stirred at rt for 16 h. The mixture was filtered through a pad of celite and the filtrate was ated in vacuo to give a brown solid. The solid was d by preparative LC ular SiOH 15-40 pm, 12 g Grace, dry g, mobile phase gradient: from CHzClz/MeOH/NHgaq 97/3/03 to 80/20/2) to give 32 mg of an off-white solid. The solid was taken up with water, triturated and sonicated. The resulting suspension was filtered off (glass frit n°5) and washed with EtZO (twice) to give 19 mg of final compound 6 as an off-white solid (15% yield). -1 9- Overall Scheme in the preparation of final products: method 7 O | CAN "0% Enrzbbsnzia'z: ) 0 M351\ O/W 9—» / N02 N l NaH,THF CH CI2 2 \ GAGA X1 10 O\/\ O I OJLN HOW /J —————————> 0201b: NC» o \\ N O/"\\//§§ | NaH, THF \ A O O/\ Br N NH2 D1 W1 sis of ediate W1 NaH (60% in oil) (2.1 g; 52.1 mmol) was added portion wise to 3-buten—l-ol (74 mL) at rt. The mixture was stirred at rt for 30 min before being added drop wise to a solution of D1 (5.97 g; 13.2 mmol) in THF (150 mL) at 0°C. The resulting mixture was then stirred at rt for 2 h 30 min and was poured in aqueous saturated solution of NH4Cl. EtOAc and saturated aqueous solution ofNaCl were added, the layers were separated and the aqueous layer was extracted with EtOAc (once). The ed organic layers were dried over MgSO4, filtered and the solvent was removed under reduced re to give 6.77 g of a yellow oil. The crude was purified by preparative LC (Irregular SiOH 15-40 urn, 120 g Grace, liquid injection, mobile phase gradient: from Heptane/EtOAc 100/0 to 50/50) to give 5.12 g of intermediate W1 as a yellow oil (83% yield).

K OzNfl 0 N Grubbs catalyst 02m | 2nd 9eneration CAN \ 0 O \ 0W U2N 9 \ o O/\ Synthesis of intermediate X1 To a solution of W1 (3 g; 6.78 mmol) in CHzClz (1.3 L) ed by N2 bubbling for 15 min was added Grubbs catalyst 211d generation (578 mg; 678 umol) at rt. The solution was stirred at rt for h. SiliaBond DMT (8.89 g; 5.42 mmol) was added and the e was stirred at rt for 20 h.

The reaction e was filtered through a pad of celite and the solvent was removed under reduced re to give a brown residue, which was combined with another batch (0.226 mmol scale). The combined residue was taken up with MeOH, sonicated and heated to give a precipitate which was filtered off to give 3.2 g of a brown solid. The crude was purified by preparative LC (irregular SiOH, 15-40 um, 220 g grace, liquid injection, mobile phase gradient: from CHzClz/EtOAc 100/0 to 50/50) to give 1.7 g of fiaction l as a pale brown solid. Fraction 1 was taken up with MeOH, sonicated and heated to give a precipitate which was filtered off to give 820 mg of fraction 2 as a pale brown solid.

The filtrate was concentrated in vacuo to give 590 mg of fraction 3 as a brown residue (impure X1). Fraction 2 was d by preparative LC (Stationary phase: Spherical bare silica 5um 150x30.0mm, mobile phase nt: from Heptane/EtOAc 85/15 to 0/100) to give 435 mg of intermediate X1 as a yellow solid (E isomer, 15% yield). on 3 was purified with another batch.

OZN / O N CAN \ o Fe,AcOH H04 l —> N )K©/0\ O water \ \ Synthesis of final compound 10 A mixture ole (430 mg; 1.04 mmol) and iron (579 mg; 10.4 mmol) in acetic acid (43 mL) and water (3 mL) was stirred at 50°C for 4 h. The mixture was concentrated until dryness. DMF was added. The mixture was sonicated, heated and filtered through a pad of celite and the celite was -21 _ rinsed with hot DMF. SiliaBond imidazole (17.9 g; 20.8 mmol) was added to the filtrate and the mixture was stirred at rt for 16 h. The mixture was filtered through celite, the celite was rinsed with DMF and the filtrate was concentrated in vacuo to give 670 mg of crude compound. The crude was purified by preparative LC (irregular SiOH, 15-40 um, 25 g Merck, mobile phase gradient: from CHzClz/MeOH/NHgaq 2 to 85/15/ 1.5) to give an off-white solid. The solid was dried at 40°C under reduced pressure during 20 h to give 295 mg of final compound 10 as an off-white solid (84% yield).

Overall Scheme in the preparation of final ts: method 8 "£1503 Wilkinson'5 catalyst O | HO— Synthesis of final compound 14 A mixture on1 (55 mg; 0.132 mmol) and iron (74 mg; 1.32 mmol) in acetic acid (5.5 mL) and water (0.4 mL) was stirred at 50°C for 20 h. More iron (37 mg; 0.66 mrnol) was added and the e was stirred at 50°C for 3 h. More iron (37 mg; 0.66 mrnol) was added and the mixture was stirred at 50°C for 20 h. The mixture was filtered through a pad of celite and the celite was rinsed with acetic acid. More iron (74 mg; 1.32 mmol) was added to the filtrate and the mixture was stirred at 50°C for 88 h. More iron (74 mg; 1.32 mmol) was added to the filtrate and the mixture was stirred at 80°C for 24 h. The cyclisation was not complete. The mixture was concentrated in vacuo to give a brown solid.

TiC13 (8.60 mL; 10.0 mrnol) was added drop wise to a on of the brown solid in C (19 mL).

The mixture was d at rt overnight. The mixture was d by addition of K2C03 powder at 0°C. The ing e was filtered through a pad of celite and the celite was washed with a solution of AcOEt/MeOH (8:2). The filtrate was concentrated in vacuo. The crude solid was purified by preparative LC ular SiOH, 15-40 um, 10 g Merck, dry loading, mobile phase gradient: from CHzClz/MeOH/NHgaq 98/2/02 to 85/15/15). The fractions containing product were combined and the t was removed in vacuo to give 20 mg of final compound 14 (12% yield ) as an off-White solid.

Overall Scheme in the preparation/Jof final products: method 9 #CH3SO2CI NEt3 A J CH2CI2 LiCI HO MsO / O\/\\ JOL ’0 OW 0 NH 0 2 N02 K2003 acetone OJLN NH3 aq / ’—> —> l ) 0 N / No2 Nal Br N Br I A / N02 \ | A1 Br N Br Br \N NH2 HO/\/\ OzN / N Grubbs catalyst O | | 2nd generation —* CAN \ O 0\Q:%O/\~\ 0% a NaH,THF CH2CI 0 2 2 0 Kg 3 \ D2 E2 /0 Fe AcOH HO—<’fl —, N \ 0 water \ o\ /O H /o H CH3SOZCI, NEt3 o CHZCIZ’LICI HO M80 21 A2 Synthesis of intermediate A2 Methanesulfonyl chloride (8.4 mL; 108 mmol) was added to a solution of Z1 (14 g; 72.1 mmol), NEt3 (20 mL; 144 mmol) and LiCl (4.6 g; 108 mmol) in dry CHzClz (980 mL). The mixture was stirred at rt for 1 h 30. Water was added and the layers were separated. The c layer was washed with water (once), dried over MgSO4, filtered and concentrated in vacuo to give 18.8 g ofA2 (96%) as a green oil.

/O O\/\ OANH A2 2 No2 K2003, acetone ii / N Nal )3 N02 Br \N / Br I A1 Br N Br Synthesis of intermediate B2 Intermediate B2 was obtained using the ure described for ediate C1 (78% yield as a yellow oil).

A O NH3 aq )3 N —> O N N02 THF I ) N02 \ | Br N Br \ Br N NH2 Synthesis of intermediate C2 Intermediate C2 was obtained using the procedure described for intermediate D1 (quantitative yield as a yellow oil). /0 OW j’ N a o p om / 2 NaH,THF I GAGA Br N NH2 \ D2 Synthesis of intermediate D2 Intermediate D2 was obtained using the procedure described for intermediate W1 (64% yield as a yellow solid).

I OZN / OzN / N Grubbs catalyst I 2nd 9enerat'onI \ O \ 03K N cm A CH2C|2 O o O/\ "1:131:03 Synthesis of intermediate E2 A solution of D2 (1 g; 2.12 mmol) in CH2C12 (400 mL) was degassed by N2 bubbling for 15 min.

Grubbs catalyst 211d generation (181 mg; 212 umol) was added and the mixture was stirred at rt for 16 h. SiliaBond DMT (2.78 g; 1.69 mmol) was added and the e was stirred at rt for 16 h. The mixture was filtered h a pad of celite and the filtrate was concentrated in vacuo to give 1.11 g of a brown oil. The crude was purified by preparative LC ular SiOH 15-40 um, 50 g Merck, mobile phase gradient: from CHzClz/EtOAc 100/0 to 90/10). The fractions containing product were combined and the solvent was removed in vacuo to give 386 mg of intermediate E2 (41%, isomer E (96.2%) + isomer Z ) as a yellow foam. 021%: NH2 Ho /N G" 0AM \ Fe,AcOH O \ —> N o 0 water \ 0\ Synthesis of final compound 15 Iron (291 mg; 5.21 mmol) was added to a on of E2 (386 mg; 0.869 mmol) in acetic acid (36 mL) and water (3 mL). The mixture was stirred at 80°C for 6 h. Iron (146 mg; 2.61 mmol) was added and the mixture was stirred at 80°C for 16 h. Iron (146 mg; 2.61 mmol) was added again and the mixture was stirred at 80°C for 5 h. The mixture was concentrated until dryness. DMF was added, the mixture was filtered through celite and the celite was rinsed with DMF. Siliabond Imidazole (18 g; 20.9 mmol) was added to the filtrate and the e was stirred at rt for 72 h.

The mixture was filtered through celite, the celite was rinsed with DMF and the filtrate was concentrated in vacuo to give 428 mg of a brown solid. The solid was taken up in CH3CN leading to precipitation. The precipitate was filtered to give 267 mg of a brown solid. The solid was purified by preparative LC (Irregular SiOH 15-40 um, 10 g Merck, dry loading, mobile phase gradient: from CHzClz/MeOH/NHgaq 95/5/05 to 85/15/1.5). The fractions containing product were combined and the solvent was removed in vacuo to give 124 mg of an off-white solid. The solid was purified by Reverse phase (Stationary phase: Sunfire-C18 5 um 19x150 mm, mobile phase gradient: from CH3CN/H20 c acid 0.1%) 5/95 to 50/50) to give 72 mg of final nd 15 (23% yield) as a white solid.

Overall Scheme in the preparation of final ts: method 10 NH2 NH2 O N / | TCII N - - N / CAN \ 0?O HO—<’ HCI 4N In dioxane | HO—<’ IN N O \ 2 THF / MeOH N O F F 16 17 (HCI salt) Synthesis of intermediate F2 Intermediate F2 was obtained with the procedures described for intermediate F1 (E isomer).

Synthesis of final compound 16 At rt, TiC13 (12.3 mL; 14.341 mmol) was added drop wise to a mixture of F2 (300 mg; 0.717 mmol) in THF (30 mL). The mixture was stirred at rt for 2 hours. The mixture was cooled down to 0°C and basified with K2C03 powder. The resulting muddy mixture was d through a pad of celite and the celite was washed with a solution of AcOEt/CHgOH 8/2. The filtrate was partially evaporated to give 175 mg of final compound 16 after filtration of a white solid and drying under vacuum pressure at 85°C (71% yield).

Synthesis of final compound 17 The hydrochloride salt was ed with 10 eq of HCl 4N in dioxane, which was added to the suspension of compound 16 (100 mg; 0.292 mmol) in CHgOH (10 mL). The precipitate was stirred for 3 h, d and dried under vacuum at 90°C overnight. The solid was lized in MeOH/CHzClz 50/50, CH3CN was added and the solvent was evaporated up to precipitation of a white solid, which was d and dried under vacuum at 90°C to give 47 mg of final compound 17 as an HCl salt (0.93 HCl, 0.51 H20 ; 42% yield).

Overall Scheme in the preparation of final products: method 11 kit £3on _, KarlaO N K THF K H2 2)]; O NH3aq OJLN PPh3 DIAD BO/KEZOZ 2 / N02 THF I Br N NH2 NH2 NH2 HO/\/ R OzNflo/V/ Srgbbs-Hmt/Ieyda 82" / n IN genera Ion CAN \ ONY 0 NaH THF . + map DCE 4 U; 0 34 NH2 NH2 )(OJLN/OYOV _4,O O LiAIH kDAN OH i Hl H2 Synthesis of intermediate H2 At -20°C under a N2 flow, G2 (22.0 g; 72.04 mmol) in THF (100 mL) was added drop wise to a suspension of LiAlH4 (3.28 g; 86.45 mmol) in THF (120 mL). The mixture was d at 0°C for l h. 3.5 mL ofwater was added dropwise, followed by 3.5 mL ofNaOH 3N and 10 mL ofwater.

The resulting mixture was d through a pad of celite and the celite was washed with EtOAc. 2014/056270 The filtrate was concentrated under reduced pressure to give 19 g of intermediate H2 as a yellow oil (quantitative yield). 0Y0)? jfizgf 231 Synthesis of intermediate 12 At 0°C, diisopropylazodicarboxylate (4.0 mL; 20.32 mrnol) was added drop wise to a mixture of Al (5.0 g; 13.55 mmol), H2 (4.28 g; 16.26 mmol) and PPh3 (5.33 g; 20.327 mmol) in THF (100 mL). The mixture was stirred at rt for 12 h. EtOAc and water were added. The layers were decanted. The organic layer was washed with water, dried over MgSO4, filtered and the solvent was evaporated. The crude compound was dissolved in Heptane/EtOAc 80/20, the precipitate was filtered off (mainly POPh3) and the filtrate was purified by chromatography. Purification was carried out by flash chromatography over silica gel (15-40 um, 220 g, Heptane/EtOAc 80/20) The pure ons were collected and evaporated to dryness to give 8.2 g of intermediate 12 (99% yield).

OYOJ/ OYOJ/ N\/\\ i 0 NH3aq j N NO / 2 Br N Br jfiifl: Synthesis of ediate J2 12 (8.2 g; 13.349 mmol) was stirred in NH4OH (100 mL) and THF (100 mL) at rt for 24 h. The mixture was half evaporated under reduced pressure. The residue was taken up with EtOAc. The c layer was washed with water, dried over MgSO4, filtered and the solvent was evaporated to give 8.15 g of intermediate J2 (quantitative . The crude compound was used directly in the next reaction step. 2014/056270 )1 HOV K o N —> OZNfl \ j/EINOZ OYN N o/V/ NaH,THF Br N +0 \GfloAOA NH2 K2 sis of intermediate K2 Under a N2 flow, NaH (60% in oil) (1.15 g; 28.64 mrnol) was added portion wise to allyl alcohol (35 mL) at rt. The mixture was stirred at rt for 30 min before being added drop wise to a solution of J2 (4.0 g; 7.26 mmol) in THF (80 mL) at 0°C. The resulting mixture was then stirred at rt for 2 h 30 min and was poured in a saturated solution of NH4Cl. EtOAc and a saturated aqueous solution ofNaCl were added, the layers were separated and the aqueous layer was extracted with EtOAc (once). The combined organic layers were dried over MgSO4, filtered and the solvent was removed under reduced re to give 4.7 g of a yellow oil. Purification was carried out by flash chromatography over silica gel (15-40 um, 80 g, CH2Cl2/Heptane 65/35). The pure fractions were collected and ated to dryness to give 2.65 g of intermediate K2 (69% yield).

NH2 NH2 k OZNfl Grubbs-Hoveyda gZN / | IN 2nd generation \ O/V/ OYN N DAN \ DCE 0:? +o A /\ J N O O )\ o 3< Synthesis of intermediate L2 Prior to the reaction, the dichloroethane was degassed by ng N2 through.

In a Slenck tube, a solution of K2 (1.3 g; 2.464 mmol) and chlorodicyclohexylborane (l M in hexane) (493 uL; 0.493 mmol) in dichloroethane (600 mL) was stirred at 80°C under N2 for l h.

Grubbs-Hoveyda catalyst 2Ild tion (609 mg; 0.493 mrnol) was added and the mixture was stirred at 120°C for 16 h. Siliabond DMT (2.98 g; 1.82 mmol) was added and the mixture was stirred at rt for 16 h. The reaction mixture was filtered through celite and the filtrate was evaporated in vacuo to give 16 g which was combined with r reaction (2.46 mmol scale) before purification (total weight to purify 3.2 g). Purification was carried out by flash chromatography over silica gel (15-40 um, 80 g, CHzClz/CHgOH: 99.5/0.5). The pure fractions were collected and evaporated to dryness to give 0.99 g of Fl (E/Z mixture of expected nd, 40% yield) and 0.65 g of F2 (starting material K2).

Fl was r purified by achiral SFC (Stationary phase: NH2 5 um 150*30 mm), Mobile phase: 92% C02, 8% MeOH) to give 664 mg of intermediate L2 (E isomer, 27% yield).

NH NH2 §2N / N N / FeAcOH N Ho— Synthesis of final compound 18 At 0°C, CF3C02H (0.455 mL) was added drop wise to a mixture of M2 (100 mg, 0.236 mmol) in CH2C12 (1 mL). The mixture was stirred at rt overnight, and then basified with a 10% solution of K2C03 in water. The precipitate was filtered off, washed with water and CH3CN, and finally dried under vacuum to afford 35 mg of final compound 18 (E , 46% yield).

Overall Scheme in the ation of final products: method 12 NH2 NH2 HO— Synthesis of final compound 23 At 0°C, CF3C02H (0.281 mL, 3.643 mrnol) was added drop wise to a mixture of N2 (62 mg, 0.146 mrnol) in CH2C12 (1 mL). The mixture was stirred at rt overnight. The mixture was basified with a 10% solution of K2C03 in water. The mixture was extracted twice with CHzClz and CH30H (80/20). The organic layer was dried over MgSO4, filtered and the solvent was evaporated. The crude compound was taken up with DMF, 2 g of SiOz 60-200 urn was added and the resulting suspension was evaporated until dryness. This residue was put on the top of a chromatography column (solid deposit). Purification was carried out by flash chromatography over silica gel (15-40 um, 25 g, CHzClz/CHgOH/NH4OH: 5). The pure fractions were collected and evaporated to dryness to give 20 mg. The fraction was taken up with CH3CN, the precipitate was filtered off and dried under vacuum to afford 18 mg of final compound 23 (38% yield). -31 _ Overall Scheme in the preparation of final products: method 13 8N / TiCI N / N HO ("Hf/KNHZ \T:’ :INEg HCI6MIn IPrOH HO 3Q N o CHgCN/MeOH 03 22 (HCI salt) Synthesis of intermediate 02 Intermediate 02 was obtained with the procedures described for intermediate X1 (E ).

Synthesis of final nd 21 At rt, TiC13 (51.5 mL; 60.128 mrnol) was added drop wise to a mixture of 02 (1.3 g; 3.006 mrnol) in THF (130 mL). The mixture was stirred at rt for 2 h. The mixture was cooled down to 0°C and then basified with K2C03 powder. The resulting muddy mixture was filtered through a pad of celite and the celite was washed with a solution of CHgOH 8/2. The filtrate was partially evaporated to give 380 mg of final compound 21 (35% yield) after filtration of a white solid and drying under vacuum at 85°C.

Synthesis of final nd 22 Compound 21 (118 mg, 0.331 mrnol) in CH30H (2 mL) + CH3CN (2 mL) was cooled down to °C. HCl (6M in isopropanol) (0.16 mL, 0.993 mrnol) was added drop wise and the mixture was stirred at rt for 1 h. The precipitate was filtered off, washed with EtzO and dried under vacuum to give 109 mg of final compound 22 as an HCl salt (0.76 HCl 0.81 H20, 83% yield).

Overall Scheme in the preparation of final products: method 14 NH2 NH2 02N / O Wlkinson's OzN / IN TiCI3 ,N / N CAN \ caaysH t | O A \ HO—< JKCEF O N 03 N O \ THF o THF/CI2-|30H 2 KC?) L F : .o HC|6MInIPrOH Ho— Synthesis of final compound 19 At rt, TiC13 (9.5 mL; 11.049 mmol) was added drop wise to a mixture of P2 (0.24 g; 0.552 mrnol) in THF (25 mL). The mixture was stirred at rt for 2 h. The mixture was cooled down to 0°C and then basified with K2C03 powder. The ing muddy e was filtered through a pad of celite and the celite was washed with a solution of AcOEt/CHgOH 8/2. The filtrate was partially evaporated to give 100 mg of final compound 19 (50% yield) after filtration of a white solid and drying under vacuum at 85°C.

Synthesis of final compound 20 Compound 19 (58 mg; 0.162 mrnol) in CH3OH (2 mL) + CH3CN (4 mL) was cooled down to °C. HCl (6M in isopropanol) (81 ML; 0.486 mmol) was added drop wise and the mixture was stirred at rt for 1 h. The precipitate was filtered off, washed with diisopropylether and dried under vacuum at 90°C to give 57 mg of final compound 20 as an HCl salt (0.88 HCl 0.04 H20, 89% yield).

Overall Scheme in the preparation of final products: method 15 O / 0 2ft PPh3/DIAD OJLN 231m\ | Br N Br O \ 2 NHsaq HOV O2N / N o N THF —’ 2 \l /V/ NO2 O N O /| NaH,THF \ DADA Br N NH2 82 T2 Grubbs—Hoveyda NH2 catalyst / . IN N 2nd generatlon AK603\ 0 Fe, AcOH HO— O N / —> N \ O DCE 2 water l 03 2): PPh3/DIAD OJLN FF 2f1 A1 Br N Br Synthesis of intermediate R2 At 0°C, ropylazodicarboxylate (3.8 mL; 19.107 mrnol) was added drop wise to a mixture of A1 (4.7 g; 12.738 mmol), Q2 (2.27 g; 12.738 mmol) and PPh3 (5 g; 19.107 mmol) in THF (100 mL). The mixture was stirred at rt for 12 h. EtOAc and water were added. The layers were decanted. The organic layer was washed with water, dried over MgSO4, filtered and the solvent was evaporated. The crude compound was purified by column chromatography over silicagel (15-40 pm; 220 g) in e/AcOEt 85/15 to 5.3 g of intermediate R2 (79% yield).

ON ON 0 O OJLN NH3 aq O N 2 THF / N02 2 / No2 \ | Br N Br Br N NH2 Synthesis of intermediate S2 R2 (5.3 g; 10.015 mmol) was stirred in THF (80 mL) and NH4OH (80 mL) at rt for 24 h. The mixture was concentrated under reduced pressure. The residue was taken up with CHzClz, the precipitate (mineral) was filtered off and the filtrate was concentrated under reduced pressure.

The crude compound was purified by column chromatography over silica gel (15-40 um; 220 g) in Heptane/AcOEt 85/15 to give 3.65 g of ediate S2 (78% yield).

O \ NH2 JL "0M 0 N —, WW | 2 N02 O MK)"\ /V/ NaH,THF N O 82 T2 Synthesis of intermediate T2 NaH (1.35 g; 33.88 mmol) was added portion wise to allyl alcohol (41 mL) at rt. The mixture was stirred at rt for 30 min before being added drop wise to a solution of S2 (4 g; 8.597 mmol) in THF (100 mL) at 0°C. The resulting mixture was then stirred at rt for 2 h 30 min and was poured in an saturated aqueous solution of NH4Cl. EtOAc and a saturated aqueous solution of NaCl were added, the layers were ted and the s layer was extracted with EtOAc (once).

The combined organic layers were dried over MgSO4, filtered and the solvent was removed under reduced re to give a yellow oil. The crude compound was purified by preparative LC ular SiOH 15-40 um, 120 g Grace, liquid injection, mobile phase nt: Heptane/EtOAc 85/15) to give 3.2 g of intermediate T2 as a yellow oil (84% yield).

WO 54859 \ NH2 Grubbs--Hoveyda catalyst 2 / | 2nd generation O OZNfl \ N O/\// OkN \ DADA DCE J U:©/NHNOE/O Synthesis of intermediate U2 A solution of T2 (1 g; 2.26 mmol) and chlorodicyclohexylborane (1M in ) (904 uL; 904.013 umol) in dry dichloroethane (540 mL) was stirred at 80°C and under N2 atmosphere for 1 h. The mixture was degassed by N2 bubbling for 15 min, Grubbs-Hoveyda catalyst 211d generation (141.6 mg; 226 umol) was added, the mixture was degassed again by N2 bubbling for min and then stirred at 120°C for 16 h. 0.25 eq of catalyst were added again and mixture was stirred at 120°C for 16 h. ond DMT (5.9 g; 3.616 mmol) was added and the mixture was stirred rt for 16 h. The e was filtered through a pad of celite and the filtrate was concentrated under vacuum to give a black oil. The crude compound was purified by preparative LC (Irregular SiOH 15-40 um, 80 g Merck, mobile phase: CH2Cl2/AcOEt 97/3). The fractions containing t were combined and the solvent was removed under vacuum to give 335 mg of intermediate U2 (E isomer, 36% yield).

U2 25 Synthesis of final compound 25 Iron (0.45 g; 8.084 mmol) was added to a e of U2 (0.335 g; 0.808 mmol) in acetic acid (24 mL) + water (5 mL). The mixture was stirred vigorously at 50°C for 5 h.

CH2Cl2 was added and the reaction mixture was filtered through a pad of celite, and then washed with acetic acid. The solvent was removed under reduced pressure. The crude was purified by chromatography over silicagel column (SiO2 15-40 um, 25 g) in CH2Cl2/CH30H/NH4OH 96/4/05 to give 154 mg of final compound 25 (56% yield). The compound was crystallized in CHgOH, filtered and dried under vacuum at 90°C to give 70 mg (25% yield).

Overall Scheme in the preparation of final products: method 16 oY?0 N\/\\ NH2 ’f1 OYN\©flN \ OW +° 0*" Br N NH2 V2 NH2 NH2 gristgiesneration 0*N \ O + O \ CAN \ CHZCIZ } KO»; 2 0 34 KG";o % W2 X2 H HO—<’N / IN CFscozH / HO_ —’ \ \ N N 0 water 0% CHch2 "3 B: N Fe,AcOH Ho— \ \ N O N 0 water CHZCIZ EL KG"H ’ 22 29 OYOJ/ NA NH2 0 Ho/\/\ H OZN / CAN —> \ O/W N H THFa" OYN "KI +0 Geo" Br N NH2 v2 Synthesis of intermediate V2 Intermediate V2 was synthesized using the procedure described for intermediate K2 with 3- butenol as starting material (3.9 g, 44% yield).

Synthesis of intermediates W2 and X2 Grubbs catalyst 211d generation (236 mg, 0.277 mrnol) was added to a mixture of V2 (1.5 g, 2.77 mmol) in dry CHzClz (400 mL). The mixture was stirred at rt under a N2 flow for 24 h. Siliabond DMT (3.6 g, 2.216 mmol) was added and the mixture was d at rt for 12 h. The mixture was filtered through , the celite was washed with CH2C12 and the filtrate was ated.

Purification was carried out by flash chromatography over silica gel (15-40 um, 80 g, CHzClz/CHgOH: 99.5/0.5) pure fractions were collected and evaporated to dryness to give 0.98 g of a mixture of W2 and X2. The two isomers were separated by achiral SFC (Stationary phase: CHIRALPAK 1C 5 um 250x20 mm), Mobile phase: 70% C02, 30% CHgOH) to give 0.805 g of intermediate W2 (E isomer, 57% yield) and 0.14 g of intermediate X2 (Z isomer, 10% .

Synthesis of final nd 26 Final compound 26 was synthesized with the procedures described for final compound 18 (1St step: Y2, 0.68 g, 99% yield; 211d step: 52 mg, 27% yield).

Synthesis of final compound 29 -38— Final compound 29 was sized with the procedures described for final compound 18 (1St step: ZZ, 0.12 g, 100% yield; 2Ild step: 8 mg, 9% yield).

Overall Scheme in the preparation of final products: method 17 /\/Br F H/ DIBAI-H o O K2003 CH3CN O CHchZ A3 03 F O\/\\ r F M 0 NH i 0 j NHsaq / No2 IAD o N | —’ 0 N NO THF \N THF } 2 Br Br /| j N02 \ /| A1 Br N Br Br \N NH2 flow OZN / N HOW O@:O//\N| OzNfi Grubbs catalyst i | 2nd generatIon' \ NaH,THF CH2CI2 )0 Kg0:;0 G3 F NH2 NH2 N N HCI (6M . . / In IPrOH) N Fe,AcOH —» HO_ Synthesis of intermediate C3 Under N2, DIBAL-H (1.2 M in e) (97 mL; 116.5 mmol) was added to a solution of B3 (9.8 g; 46.6 mmol) in dry CHzClz (250 mL) at 0°C. The reaction mixture was stirred at 0°C for 1 h, and then 1 h at rt. Water was added, The c layer was separated from the aqueous layer, dried over MgSO4, d and concentrated under vacuum to give 8.4 g of intermediate C3 (99% yield). The crude compound was used directly in the next reaction step.

F oA OJLNH C3 0 j No2 PPh3/DIAD / oiN | 2 NO2 Br \N THF / Br | A1 Br N Br Synthesis of intermediate D3 Intermediate D3 was synthesized using the procedure bed for intermediate R2 with C3 as starting material (1.9 g, 88% yield).

F OW F OW JL 0 NH3aq j N —> O N N02 THF I 2 N02 \ | Br N Br \ Synthesis of intermediate E3 Intermediate E3 was synthesized using the ure described for intermediate S2 with D3 as starting material (1.8 g, 93% yield).

F OA 0 HOW OZN / 0 N O \ OW 2 N02 NaH,THF / A /\ | 0 O Br N NH2 F Synthesis of intermediate F3 Intermediate F3 was synthesized using the procedure described for intermediate Wl with E3 as starting material (0.65 g, 66% yield).

OzN / N Grubbs catalyst O | 2nd generation O \ CAN E N OW A CHZCIZ O o O/\ Synthesis of intermediate G3 Intermediate G3 was synthesized using the procedure described for intermediate X1 with intermediate F3 as starting material (E isomer, 520 mg, 19% yield).

NH2 NH2 own N / Fe AcOH H04m N \ 0 water \ Synthesis of final compound 27 Final compound 27 was synthesized using the ure described for final nd 10 with intermediate G3 as starting material (174 mg, 42% yield).

W0 54859 NH2 NH2 Flo—(flN / N . . N HC|(6M m IPrOH) / N H04 I N \ N \ o —> o \ CH3OH/CH3CN o \ 27 t F 28 F Synthesis of final compound 28 Final compound 28 was synthesized using the procedure described for final compound 20 with compound 27 as starting al (101 HCl 0.89 H20, 95 mg, 69% yield).

Overall Scheme in the preparation of final products: method 18 NH2 NH2 Wilkinson's N N / CAN \gzNfi Fe/AcOH catalyst gzNfi/ HO— Synthesis of final compound 32 A mixture of H3 (150 mg; 0.345 mmol) and iron (190 mg; 3.45 mmol) in acetic acid (13 mL) and water (1.5 mL) was stirred at 50°C for 5 h. CH2C12 was added and the reaction mixture was filtered through a pad of celite and concentrated under vacuum. The crude compound was taken up with DMF, d through a pad of celite and concentrated. The solid was pre-purified by chromatography over silicagel column (SiOz 63-200 um. 80g) in CHzClz/CHgOH/NH4OH( 98/2/01 to 90/10/05). A second purification by achiral SFC (Stationary phase: Whelk Ol (S,S) um 250*2l.l mm), Mobile phase: 60% C02, 40% CH3OH (0.3% iPrNH2)) afforded 27 mg of final compound 32 (22% yield).

Overall Scheme in the preparation of final products: method 19 F O\/\ 0 R OZNfl / Grubbs—Hoveyda O2N 2)]; \ Z HO/\/ | catalyst o \ . I 2 d genera Iont N O n CAN \ NaH THF 0 o/\ CH20|2 } O$\ I3 \q 1/0 J3 F HCI (6M m IPrOH) Tim Ho— o THF \ CH3OH/CH3CN \ \ 0 o F 31 F HCIsaIt F O\/\ 0 R 02N / N / 2): Ho/\/ | N O NaH THF 0 o/\ Synthesis of ediate 13 Intermediate 13 was synthesized using the procedure described for intermediate T2 (4.2 g, 83%).

NH2 NH2 | OZN / Grubbs—Hoveyda | f catalyst o \ N 0 2nd generation §2Nfi I3 Jifigj> Synthesis of intermediate J3 Intermediate J3 was synthesized using the procedure described for ediate Fl (isomer E, 125 mg, 17%).

NH2 NH2 O2N / N O N N I / IN . . / 2K \ TiCI3 Ho— Synthesis of final compound 31 Final compound 31 was synthesized using the ure described for final compound 22 (0.98 HC10.15 H20, 72 mg, 59% yield).

Overall Scheme in the preparation of final products: method 20 o/ 0/ H/ OH WE" o KZCO3/CH3CN HO K3 L3 0 NH i O o 0 2 L3 / N02 NHsaq 0 N OJLN | PPh /D|AD NO THF Br \N Br THF3 /| 2 2 N02 \ /| A1 Br N Br Br \N NH2 / NH O NHZ 2 Grubbs—Hoveyda HOV OZN / 2 / N catalyst N O | 2nd generation I —. \ N O/V/ —> O>\\N \ O NaH, THF T OAOA dry DCE ) 1\ 03 P3 N / TICI3. N H04<, I O 36 OH /\/E"r KZCO3/CH3CN HO K3 Synthesis of ediate L3 A11y1 bromide (1.7 mL; 19.6 mmol) was added to a solution ofK3 (3 g; 17.8 mmol) and K2C03 (2.7 g; 19.6 mmol) in CH3CN (90 ml). The mixture was stirred at 90°C for 20 h, and then filtered. The e was concentrated under vacuum. The crude product was taken up with CH2C12 and an aqueous solution ofNaOH 5%. The layers were separated and the organic layer was dried over MgSO4, filtered and the solvent was removed under reduced pressure to give 3 .9 g of intermediate L3 (quantitative yield). The crude compound was used directly in the next reaction step. o NH O 0 ’II L3 0*"ICE f PPh/DMD NO2 3 Br ‘\N Br THF "J//Efl:fl:\ A1 Br N Br Synthesis of ediate M3 At 0°C, ropylazodicarboxylate (4.8 mL; 24.36 mrnol) was added drop wise to a mixture of Al (6 g; 16.2 mmol), L3 (3.2 g; 15.36 mmol) and PPh3 (6.4 g; 24.36 mmol) in THF (120 mL).

The mixture was stirred at rt for 12 h. EtOAc and water were added. The layers were decanted.

The organic layer was washed with water, dried over MgSO4, filtered and the solvent was evaporated. 20 mL of Heptane/AcOEt 70/30 were added to precipitate a large part of the formed PPth, which was removed by filtration. The crude t was purified by preparative LC (Irregular SiOH 15-40 um, 120 g Interchim, mobile phase Heptane/EtOAc 80/20) to give 8 g of intermediate M3 (88% yield).

' I ft 0 O fgo NH3 aq 0 N _, OJLN /) No2 THF /, /) N02 | // \ | Br N Br Br \N NH2 Synthesis of intermediate N3 M3 (8.8 g; 15.7 mmol) was d in THF (120 mL) and NH4OH (120 mL) at rt for 24 h. The mixture was concentrated under reduced pressure. The residue was taken up with CH2C12, the precipitate (mineral) was filtered off and the filtrate was dried over MgSO4, filtered through a pad of celite and concentrated under vacuum. The crude product was d by ative LC (Irregular SiOH 15-40 um, 120 g Interchim, mobile phase Heptane/EtOAc 80/20) to afford 3 g of intermediate N3 (38% yield). of / o o o NH2 on W JG; «N )fiNOZ O \ CV NaH,THF Br \N NH2 3 / DADA Synthesis of intermediate 03 NaH (60% in oil) (0.93 g; 23 mmol) was added portion wise to allyl alcohol (28 mL) at rt. The mixture was stirred at rt for 30 min before being added drop wise to a on ofN3 (2.9 g; 5.85 mmol) in THF ( 70 mL) at 0°C. The ing mixture was then stirred at rt for 2 h 30 min and was poured into a saturated aqueous on ofNH4Cl. EtOAc and a saturated aqueous solution ofNaCl were added, the layers were separated and the aqueous layer was extracted with EtOAc (once). The combined organic layers were dried over MgSO4, filtered and the solvent was removed under reduced pressure to give a yellow oil. The crude t was purified by preparative LC (Irregular SiOH 15-40 um, 120 g Grace, liquid injection, mobile phase e/EtOAc 80/20) to give 2.4 g of ediate 03 (87% .

Grubbs-Hoveyda O | n generation % \ N O/V/ —> OWN \ o A dryDCE / \ o O/\ ) Synthesis of intermediate P3 The reaction was carried out on three batches.

A solution of 03 (0.8 g; 1.7 mmol) and chlorodicyclohexylborane (1M in hexane) (0.68 mL; 0.68 mrnol) in dry dichloroethane (400 mL) was stirred at 80°C and under N2 atmosphere for l h.

The mixture was degassed by N2 bubbling for 15 min, Grubbs-Hoveyda catalyst 211d generation (110 mg; 0.17 mol) was added, the mixture was degassed again by N2 bubbling for 15 min and then stirred at 120°C for 16 h. 0.050 eq of catalyst (49 mg, 0.084 mrnol) were added and mixture was stirred at 120°C for 7 h. Siliabond DMT (3.3 g; 2.03 mmol) was added and the mixture was stirred rt for 16 h. The mixture was filtered through a pad of celite and the e was concentrated under vacuum to give a black oil. The crude product was purified by preparative LC (Irregular SiOH 15-40 um, 80 g Interchim, mobile phase Heptane/EtOAc 65/35) to give 190 mg of intermediate P3 (isomer E, 25% yield).

Synthesis of final compound 36 At rt, T1C13 (19.3 mL; 22.5 mmol) was added drop wise to a mixture of P3 (500 mg; 1.125 mmol) in THF (90 mL). The mixture was stirred at rt for 2 h. At 0°C, the mixture was basified with K2C03 powder. The resulting muddy mixture was filtered through a pad of celite and celite was washed with a solution of CHzClz/CHgOH (90/10). The filtrate was concentrated under reduced re. The residue was taken up in MeOH. The white solid was filtered off and dried under vacuum. The product was purified by preparative LC (Irregular SiOH 15-40 um, 40 g Interchim, mobile phase CHzClz/CHgoH/NH4OH 98/2/01) to give 140 mg of final compound 36 (34% .

LCMS methods: General grocedure VDR2 (for methods 30xx.0/g) The LC measurement was med using a UPLC (Ultra Performance Liquid Chromatography) Acquity (Waters) system comprising a binary pump with degasser, an autosampler, a diode-array detector (DAD) and a column as ed in the respective methods below, the column is hold at a temperature of 40°C. Flow from the column was brought to a MS detector. The MS detector was configured with an electrospray ionization source. The capillary needle voltage was 3 kV and the source temperature was maintained at 130 0C on the o (triple quadrupole mass spectrometer from Waters). Nitrogen was used as the nebulizer gas. Data ition was performed with a Waters-Micromass MassLynx-Openlynx data system.

Method V3018V3001 In addition to the general procedure VDR2: Reversed phase UPLC was carried out on a Waters Acquity BEH (bridged ethylsiloxane/silica hybrid) C18 column (1.7 um, 21 x 100 mm) with a flow rate of 0.343 ml/min. Two mobile phases (mobile phase A: 95 % 7 mM ammonium e / 5 % acetonitrile; mobile phase B: 100 % acetonitrile) were employed to run a gradient condition from 84.2 % A and 15.8 % B (hold for 0.49 minutes) to 10.5 % A and 89.5 % B in 2.18 minutes, hold for 1.94 min and back to the l conditions in 0.73 min, hold for 0.73 minutes. An injection volume of 2 ul was used. Cone voltage was 20V for positive and negative -48— ionization mode. Mass spectra were acquired by scanning from 100 to 1000 in 0.2 seconds using an interscan delay of 0.1 seconds.

Table 1. Compounds of formula (I).

Mass LCMS Ret Exact Synthesis # STRUCTURE Found Tlme,. NMR Mass method [M+H] Method 1H NMR (500 MHz, DMSO-d6) 8 10.06 (s, 1H), N / :1 1.96, 7.36 (s, 1H), 7.20 (t, .1: 7.9 HO{/Q V3018V3 Hz, 1H), 6.76 — 6.93 (m, 1 N 0:? 324.1 325 001 Method 1 2H), 6.05 (s, 1H), 5.94 (dt, .1 KQ/O = 6.0, 16.1 Hz, 1H), 5.43 .64 (m, 3H), 4.84 (s, 2H), 4.40 — 4.66 (m, 4H) 1H NMR (400 MHz, DMSO-d6) 8 10.04 (br. s., NH2 1H), 7.49 (s, 1H), 7.17 (t, .1 Nfl 2.02, = 7.9 Hz, 1H), 6.69 - 6.83 2 HOK’N \ | 0O? 326.1 (rn, 2H), 6.15 (s, 1H), 5.54 327 Method 2 Kg 001 (s, 2H), 4.89 (s, 2H), 4.28 (t, .1: 6.3 Hz, 2H), 4.14 (t, .1: 6.6 Hz, 2H), 1.34 — 1.62 (m, 1H NMR (500 MHz, DMSO-d6) 8 10.11 (br. s., 1H), 7.22 (t, .1: 7.6 Hz, 1H), 7.12 (br. s., 1H), 7.09 2.3, (d, .1: 7.6 Hz, 1H), 7.05 (d, .1: 7.6 Hz, 1H), 5.74 (s, 3 322‘] 323 V38(1)§V3 Method 3 1H), 5.51 — 5.63 (m, 3H), .03 (td, .1: 7.2, 14.9 Hz, 1H), 4.93 (s, 2H), 4.15 — 4.26 (m, 2H), 3.15 — 3.23 (m, 2H), 2.24 — 2.33 (m, 2H) Mass LCMS Ret Exact Synthesis STRUCTURE Found Time, NMR Mass method [M+H] Method 1H NMR (500 MHz, DMSO-d6) 8 10.20 (br. s., 1H), 7.34 (s, 1H), 7.21 (t, J = 7.3 Hz, 1H), 7.06 (d, .1: 2.36, 7.3 Hz, 1H), 6.97 (d, .1: 7.3 V3018V3 324.2 325 Method 4 Hz, 1H), 5.59 (s, 2H), 4.93 (s, 2H), 3.91 — 4.03 (m, 2H), 2.55 - 2.62 (m, 2H), 1.59 - 1.71 (m, 2H), 1.12 — 1.27 (m, 4H) 1H NMR (400 MHz, DMSO-d6) 8 9.91 (br. s., 1H), 8.05 (d, .1: 4.6 Hz, 1H), 7.38 (d, .1: 8.6 Hz, 1H), 7.27 (dd, .1: 4.6, 8.6 1.85, Hz, 1H), 6.20 (s, 1H), 5.82 V3018V3 339.1 340 Method 5 001 (dt, .1: 7.0, 15.6 Hz, 1H), .68 (dt, .1: 7.1,15.6 Hz, 1H), 5.46 (s, 2H), 4.91 (s, 2H), 4.33 (d, .1: 7.1 Hz, 2H), 4.12 — 4.27 (m, 2H), 2.36 — 2.46 (m, 2H) 1H NMR (400 MHz, DMSO-d6) 8 9.92 (s, 1H), 8.09 (d, .1: 4.0 Hz, 1H), 7.43 (d, .1: 8.1 Hz, 1H), 1.85, 7.30 (dd, .1: 4.0, 8.1 Hz, V3018V3 1H), 6.40 (s, 1H), 5.51 (s, 341.1 342 Method 6 001 2H), 4.96 (s, 2H), 4.15 (t, .1 = 6.1 Hz, 2H), 3.97 — 4.10 (m, 2H), 1.81 — 1.91 (m, 2H), 1.68 — 1.78 (m, 2H), 1.52 — 1.65 (m, 2H) 1H NMR (400 MHz, 1.84, 6) 8 10.03 (br. s., V3018V3 1H), 7.36 (d, .1: 2.0 Hz, 354.1 355 Method 1 001 1H), 6.91 (d, .1: 8.1 Hz, 1H), 6.80 (dd, .1: 2.0, 8.1 Hz, 1H), 6.06 (dt, .1: 6.0, 2014/056270 Mass LCMS Ret Exact Synthesis STRUCTURE Found Time, NMR Mass method [M+H] Method 16.2 Hz, 1H), 5.93 (s, 1H), .54 (s, 2H), 5.41 (dt, .1: .6, 16.2 Hz, 1H), 4.78 (s, 2H), 4.50 — 4.67 (m, 2H), 4.28 — 4.48 (m, 2H), 3.71 (s, 1H NMR (400 MHz, DMSO-d6) 8 10.03 (br. s., 1H), 7.54 (br. s., 1H), 6.87 (d, .1: 8.1 Hz, 1H), 6.76 (d, 1.86, J: 8.1 Hz, 1H), 6.24 (br. s., V3018V3 356.1 357 Method 2 001 1H), 5.53 (br. s., 2H), 4.82 (br. s., 2H), 4.19 — 4.32 (m, 2H), 4.01 — 4.16 (m, 2H), 3.68 (br. s., 3H), 1.34 - 1.60 (m, 4H) 1H NMR (400 MHz, DMSO-d6) 5 9.73 (s, 1H), 7.57 (s, 1H), 7.16 (t, .1: 7.6 Hz, 1H), 7.02 (d, .1: 7.6 Hz, 2.36, 1H), 6.89 (d, .1: 7.6 Hz, V3018V3 Method 1 1H), 5.33 (t, .1: 6.6 Hz, 323.2 324 001 Method 2 1H), 5.25 (s, 1H), 5.15 (s, 2H), 4.85 (s, 2H), 2.91 (q, .1 = 6.6 Hz, 2H), 2.58 — 2.72 (m, 2H), 1.59 — 1.85 (m, 2H), 0.96 — 1.21 (m, 4H) 1H NMR (400 MHz, DMSO-d6) 8 10.05 (br. s., 1H), 7.20 (t, .1: 7.8 Hz, 1H), 6.92 (d, .1: 7.8 Hz, 2.22, 1H), 6.89 (s, 1H), 6.77 (d, .1 V3018V3 = 7.8 Hz, 1H), 6.12 (s, 1H), 338.1 339 Method 7 001 5.50 — 5.64 (m, 3H), 5.35 (dt, J=4.5, 16.2 Hz, 1H), 4.87 (s, 2H), 4.58 (d, .1: 4.5 Hz, 2H), 4.24 (t, J: 5.1 Hz, 2H), 2.21 — 2.32 (m, 2H) Mass LCMS Ret Exact , . Synthes1s # URE Found Tlme, NMR Mass method [M+H] Method 1H NMR (500 MHz, DMSO-d6) 5 10.07 (s, 1H), 7.32 (s, 1H), 7.18 (t, .1: 7.7 Hz, 1H), 6.82 (d, .1: 7.7 Hz, NH2 1H), 6.79 (dd, .1: 1.7, 7.7 H64N l ‘/N 2.33, Hz, 1H), 5.98 (dt, .1: 7.7, V3018V3 11 <3)? 15.5 Hz, 1H), 5.80 (s, 1H), 3522 353 M61116d 1 U 001 5.56 (s, 2H), 5.51 (td, .1: 58,155 Hz, 1H), 4.84 (s, 2H), 4.71 (d, .1: 5.8 Hz, 2H), 3.96 (t, .1: 7.7 Hz, 2H), 1.92 — 2.07 (m, 2H), 1.49 — 1.64 (m, 2H) NH2 1H NMR (400 MHz, |_|O_ | /N s., 2.21, 22 356'] 357 001 7.07 (dd, .1: 1.9, 8.2 Hz, 1H), 6.85 — 6.99 (m, 1H), 6.64 (s, 1H), 5.80 (dt, .1: Mass LCMS Ret Exact Synthesis STRUCTURE Found Time, NMR Mass method [M+H] Method 7.2, 15.6 Hz, 1H), 5.59 (dt, .1: 5.7, 15.6 Hz, 1H), 4.98 (s, 2H), 4.68 (d, .1: 5.7 Hz, 2H), 4.41 — 4.59 (m, 2H), 2.38 — 2.50 (m, 2H) 1H NMR (500 MHz, 6) 8 9.97 (br. s., 1H), 7.05 (s, 1H), 6.90 (t, J = 7.7 Hz, 1H), 6.42 (d, J: 1.83, 7.7 Hz, 1H), 6.38 (d, J: 7.7 V3018V3 Method Hz, 1H), 6.35 (s, 1H), 5.33 - 23 325.2 326 001 1 2 5.58 (m, 3H), 4.77 (s, 2H), 4.17 (t, J: 6.8 Hz, 2H), 3.20 (q, .1: 6.4 Hz, 2H), 1.42 — 1.52 (m, 2H), 1.32 — 1.41 (m, 2H) 1H NMR (500 MHz, DMSO-d6) 5 10.04 (br. s., 1H), 7.77 (d, J: 7.6 Hz, 1H), 7.10 (dd,.]= 87,112 2.08, Hz, 1H), 6.78 (br. s., 1H), V3018V3 Method 24 344.1 345 6.28 (s, 1H), 5.56 (s, 2H), 001 1 4 4.86 (s, 2H), 4.28 — 4.47 (m, 2H), 4.04 — 4.23 (m, 2H), 1.52 - 1.66 (m, 2H), 1.31 — 1.50 (m, 2H) 1H NMR (500 MHz, DMSO-d6) 8 10.07 (br. s., 1H), 7.18 (t, J: 7.9 Hz, 1H), 7.14 (s, 1H), 6.73 - 2.13, 6.87 (m, 2H), 5.96 (dt, .1: V3018V3 Method 5.0, 15.7 Hz, 1H), 5.90 (s, 338.1 339 001 1 5 1H), 5.57 (s, 2H), 5.37 (dt, .1 = 5.8, 15.7 Hz, 1H), 4.86 (s, 2H), 4.58 (d, J: 5.8 Hz, 2H), 4.22 (t, J: 5.0 Hz, 2H), 2.27 — 2.42 (m, 2H) Mass LCMS Ret Exact Synthesis # STRUCTURE Found Tlme,. NMR Mass method [M+H] Method 1H NMR (500 MHz, DMSO-d6) 5 10.04 (br. s., 1H), 6.95 (t, .1: 7.2 Hz, 1H), 6.51 (d, .1: 7.2 Hz, N "\"2 1H), 6.46 (dd, .1: 1.3, 7.2 H04 l /N 2.02, Hz, 1H), 6.40 (s, 1H), 6.16 N 3 Method 26 kON('13 (5, 1H), 5.97 (t, J: 6.3 Hz, 337.2 338 001 16 1H), 5.59 (s, 2H), 5.43 (dt, .1 = 63,155 Hz, 1H), 5.22 (dt, .1: 5.0, 15.5 Hz, 1H), 4.76 (s, 2H), 4.23 (t, .1: 5.2 Hz, 2H), 3.56 (t, .1: 5.0 Hz, 2H), 2.18 — 2.30 (111,2H) 1H NMR (500 MHz, DMSO-d6) 5 10.11 (br. s., NH2 1H), 6.77 (d, .1: 9.1 Hz, N \N 1H), 6.71 (s, 1H), 6.63 (dt, .1 Ho— HO— Forty microliters of cells were then dispensed into each well in 384-well plates, where 200 nL of compound in 100% DMSO was already present. Following 6 hours incubation at 37°C, 5% CO2, the luciferase ty was determined by adding 15 ul of Steady Lite Plus substrate (Perkin Elmer) to each well and readout med on a ViewLux ultraHTS microplate imager (Perkin Elmer). Dose response curves were generated from measurements performed in quadruplicates.

Lowest effective concentrations (LEC) values, defined as the concentration that induces an effect which is at least two fold above the standard deviation of the assay, were determined for each compound.

In parallel, a similar dilution series of compound was used (200 nL of compound in 100% DMSO) with 40 ML per well of cells ected with uc reporter construct alone (1.25 x 105 cells/mL). Six hours after incubation at 37°C, 5% CO2, the luciferase activity was determined by adding 15 ul of Steady Lite Plus substrate (Perkin Elmer) to each well and t performed on a ViewLux ultraHTS microplate imager (Perkin Elmer). Counterscreen data is reported as LEC.

Measurement of eron production in human PBMC Activation of human TLR7 results in robust production of interferon by plasmacytoid tic cells present in human blood. The potential of compounds to induce interferon was evaluated by determination of interferon in the conditioned media from peripheral blood mononuclear cells (PBMC). The presence of interferon in the samples was determined, using an interferon reporter cell line stably sing an interferon-stimulated responsive elements (ISRE)-luc reporter uct. The ISRE element with sequence TAGTTTCACTTTCCC is highly responsive to the STATl-STAT2-IRF9 transcription factor, which becomes ted upon binding of IFN-I to the IFN receptor. Briefly, PBMCs were prepared from buffy coats of at least two donors using a standard Ficoll fugation protocol. Isolated PBMCs were resuspended in RPMI medium supplemented with 10% human AB serum and 2 X 105 cells/well were dispensed into 384-well plates containing compounds (70 uL total ). After overnight incubation of the PBMCs with the compounds, 10 uL of supernatant was transferred to 384-well plates containing 5 x 103 HEK—ISRE-luc cells/well in 30 uL (plated the day before). ing 24 hours of incubation, activation of the ISRE elements was measured by assaying luciferase activity using 40 uL/well Steady Lite Plus substrate (Perkin Elmer) and measured with ViewLuX ultraHTS microplate imager (Perkin Elmer). The ating activity of each compound on the HEK—ISRE-luc cells was reported as LEC. The LEC in turn indicates the degree of ISRE activation on er of a defined amount of PBMC culture medium. Recombinant interferon alfa-2a on-A) was used as a standard control compound.

The LEC values for the compounds in table 2 on HEK293 TLR8-NFKB-luc and HEK293 NFKB- luc where greater than the highest tested concentration (> 10 uM for compound 4 and > 25 uM for all other compounds).

Table 2. Compounds of formula (I) n represents the number of ments performed.

HEK293 PBMC STRUCTURE TLR7-NFKB-luc n HEK-ISRE-luc n (LEC; HM) (LEC; HM) 2.88 8 0.30 8 KC/O 4.47 1 0.93 2 2014/056270 HEK293 PBMC STRUCTURE TLR7—NFKB-luc HEK-ISRE-luc n (LEC; HM) (LEC; HM) 0.27 0.033 4 2.38 2.56 2 MnN / N N \ 0 2.14 0.082 2 ofl) N \ o 1 0.16 2 ofl) N 0 / 3.88 0.29 2 N / N N O 7.1 0.58 2 N N 11.09 10.87 2 HEK293 PBMC STRUCTURE FKB-luc HEK-ISRE-luc n (LEC; uM) (LEC; uM) 0.78 0.25 4 1.25 0.45 2 1.08 0.3 2 1.71 0.15 2 7.01 2.4 2 0.18 0.04 2 -62— # HEK293 PBMC URE TLR7—NFKB-luc HEK-ISRE-luc (LEC; HM) (LEC; HM) HHNNflO 16 0:1 2.02 0.47 N / N Ho— N \ N / O 188 037 4 26 H \ ' ' N \ N H04 | N / 27 o 1.35 0.14 2 WO 54859 # HEK293 PBMC STRUCTURE TLR7-NFKB-luc HEK-ISRE-luc n (LEC; HM) (LEC; HM) N \ H04 N N / \ 0.91 0.15 2 ,HCI KQO MnN \ N / O 29 . 0.4 8 2 N / N Ho 33—

Claims (8)

Claims

1. Compound having a (I) and pharmaceutically accepted salts thereof, wherein X isO, NH or S, Y represents an aromatic ring or heterocyclic ring comprising at least a nitrogen, ally 10 substituted by one or more substituents independently selected from C1-6alkyl, C1-4alkoxy, trifluoromethyl or halogen, Z represents C1-10 saturated or rated alkyl optionally substituted by an alkyl or alkylhydroxyl; or Z represents C1-6alkyl -NH-C(O)- C1-6alkyl- , C 1-6 alkyl-NH- or C1-6alkyl O)- C1- 15 6alkyl -O-; or Z represents C1-10alkyl -O- wherein said alkyl is unsaturated or ted and can optionally be substituted by an alkyl or alkylhydroxyl , or Z represents kyl-O-C1-6alkyl- wherein said alkyl is unsaturated or saturated and can optionally be substituted by an alkyl or alkylhydroxyl 20 or Z represents C1-6alkyl-O-C1-6alkyl-O- wherein said alkyl is unsaturated or saturated and can optionally be substituted by an alkyl or alkylhydroxyl.

2. Compound according to claim 1 having one of the following formula’s selected from the group of:

3. Compound according to claim 1 having one of the ing formula’s selected from the group of: N N N O 5

4. A ceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof according to any one of claims 1 to 3 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

5. A compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph f according to any one of claims 1 to 3, or a ceutical composition ing to 10 claim 4 for use as a medicament.

6. A compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof according to any one of claims 1 to 3, or a pharmaceutical composition according to claim 4, for use in the ent of a disorder in which the modulation of TLR7 is involved.

7. Use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or 15 polymorph thereof according to any one of claims 1 to 3, or a ceutical composition according to claim 4, in the manufacture of a medicament for the treatment of a disorder in which the modulation of TLR7 is involved.

8. A compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph f according to claim 1, substantially as herein described with reference to any one of the Examples and/or